BridgeMD
New treatment option for Substance Use Disorder
Official title Personalized Approach to Healthy Use and Recovery (PATH) Trial
ClinicalTrials.gov ID: NCT06580457
What this study is testing
- What it's testing
- An important part of substance use treatment for many people is learning what triggers their substance use and urges, and how they can better manage those triggers. In this study, the investigators will generate a model for each individual that shows likely causal links between their substance use, urges, and comorbid symptoms (e.g., anxiety, depression, and PTSD), and the investigators will examine these models as a group to draw conclusions about common causes for substance use (and recovery) among Veterans with substance use disorders.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- for this study are intended to include most Veterans with SUD
- are current probable SUD as indicated by:
- a clinical score on the alcohol use disorders identification test (AUDIT) or drug use disorders identification test (DUDIT)
- past-month substance use
- a reliable access to a smartphone, tablet, or other device with capability of accessing and completing surveys throughout the day
You likely can't join if
- exclusion criteria are being under the influence of a judgment-impairing substance at the time of consent (e.g., cannabis, alcohol, illicit opioids)
- participants will be invited to return another day
- being legally compelled to complete treatment
- or being under civil commitment
- due to lack of ability to give autonomous consent in these situations
See the full eligibility criteria
- for this study are intended to include most Veterans with SUD
- are current probable SUD as indicated by:
- a clinical score on the alcohol use disorders identification test (AUDIT) or drug use disorders identification test (DUDIT)
- past-month substance use
- a reliable access to a smartphone, tablet, or other device with capability of accessing and completing surveys throughout the day
- this will exclude those who are currently completing inpatient treatment
- exclusion criteria are being under the influence of a judgment-impairing substance at the time of consent (e.g., cannabis, alcohol, illicit opioids)
- participants will be invited to return another day
- being legally compelled to complete treatment
- or being under civil commitment
- due to lack of ability to give autonomous consent in these situations
The study team makes the final eligibility decision.
Where it's taking place
- Minneapolis, Minnesota, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Minneapolis, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.